文献速递炎症性肠病肝病

炎症性肠病与乳糜泻患者乙型肝炎疫苗接种效果研究

Effectiveness of Hepatitis B Vaccination for Patients With Inflammatory Bowel and Celiac Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-03-31

该回顾性队列研究基于罗切斯特流行病学项目,纳入2000年1月1日至2019年12月31日明尼苏达州奥姆斯特德县首次诊断的1264例炎症性肠病或乳糜泻患者。351例在索引日期前接种至少2剂乙肝疫苗且索引日期后检测表面抗体者中,保护性抗体率随时间下降,末次接种后5至10年为45%、15至20年为41%。中位随访9.4年期间1258例患者均无新发乙肝感染。

要点

  • 炎症性肠病或乳糜泻患者接种乙肝疫苗后保护性抗体率随时间下降,5至10年为45%,15至20年为41%。
  • 末次接种后15年内,对照人群保护性抗体率持续高于炎症性肠病或乳糜泻患者。
  • 中位随访9.4年期间1258例患者无新发乙肝感染。

核心结论

  • 对已完成乙肝疫苗接种的炎症性肠病或乳糜泻患者,常规检测乙肝表面抗体滴度可能并无必要。
  • 需在其他环境和人群中进一步研究以确认这些发现。

研究设计与样本

  • 利用罗切斯特流行病学项目开展的回顾性队列研究。
  • 纳入2000年1月1日至2019年12月31日期间居住于明尼苏达州奥姆斯特德县、首次诊断为炎症性肠病或乳糜泻的患者(索引日期)。
  • 从健康记录中获取乙肝病毒筛查结果。
  • 1264例新发炎症性肠病或乳糜泻病例中,仅6例在索引日期前诊断乙肝病毒感染。
  • 351例患者在索引日期前有至少2剂乙肝疫苗接种记录,且在索引日期后检测了乙肝表面抗体滴度。

主要发现

  • 乙肝保护性抗体滴度(≥10 mIU/mL)比例随时间下降后趋于平稳,末次乙肝疫苗接种后5至10年为45%,15至20年为41%。
  • 对照人群保护性抗体比例也随时间下降,且在末次乙肝疫苗接种后15年内持续高于炎症性肠病或乳糜泻患者。
  • 1258例炎症性肠病或乳糜泻患者在中位随访9.4年(四分位距5.0至14.1年)期间均无新发乙肝病毒感染。

临床怎么用

  • 作者认为,对已完成疫苗接种的炎症性肠病或乳糜泻患者,常规检测乙肝表面抗体滴度可能并无必要。

局限性

  • 需在其他环境和人群中进一步研究以确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Guidelines recommend measuring antibody (Ab) titers to hepatitis B virus (HBV) after vaccination for patients with inflammatory bowel disease (IBD) or celiac disease (CD) ("patients with IBD/CD") and revaccinating when titers are low. Few data, however, support this recommendation. We aimed to compare effectiveness of HBV vaccination (immunity and infection rates) for patients with IBD/CD vs matched referents. METHODS: Using the Rochester Epidemiology Project, we performed a retrospective cohort study of patients first diagnosed with IBD/CD (index date) while residing in Olmsted County, Minnesota, from January 1, 2000, through December 31, 2019. HBV screening results were obtained from health records. RESULTS: In 1264 incident cases of IBD/CD, only 6 HBV infections were diagnosed before the index date. A total of 351 IBD/CD cases had documented receipt of 2 or more HBV vaccines before their index date and had hepatitis B surface antigen Ab (anti-HBs) titers measured after their index date. The proportion of patients with HBV-protective titers (≥10 mIU/mL) decreased with time before plateauing, with protective titer rates of 45% at 5 up to 10 years and 41% at 15 up to 20 years after the last HBV vaccination. The proportion of referents with protective titers also decreased with time and was consistently higher than the levels of patients with IBD/CD within 15 years after the last HBV vaccination. However, no new HBV infection developed in any of 1258 patients with IBD/CD during a median follow-up of 9.4 years (interquartile range, 5.0-14.1 years). CONCLUSIONS: Routine testing of anti-HBs titers may not be indicated for fully vaccinated patients with IBD/CD. Additional studies are needed to confirm these findings in other settings and populations.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ulrich JA, Habash NW, Ismail YA, et al. Effectiveness of Hepatitis B Vaccination for Patients With Inflammatory Bowel and Celiac Disease. Clin Gastroenterol Hepatol. 2023. PMID: 37004970. doi:10.1016/j.cgh.2023.03.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。